Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F.

Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x. No abstract available.

2.

Response to "Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions" by Heidel et al.

Barosi G, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barbui T.

Leukemia. 2018 Sep 28. doi: 10.1038/s41375-018-0259-x. [Epub ahead of print] No abstract available.

PMID:
30267006
3.

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F.

J Hematol Oncol. 2018 Sep 24;11(1):122. doi: 10.1186/s13045-018-0661-x.

4.

Exposure of Owned Dogs and Feeding Ticks to Spotted Fever Group Rickettsioses in Central Italy.

Stefanetti V, Morganti G, Veronesi F, Gavaudan S, Capelli G, Ravagnan S, Antognoni MT, Bianchi F, Passamonti F.

Vector Borne Zoonotic Dis. 2018 Aug 21. doi: 10.1089/vbz.2018.2303. [Epub ahead of print]

PMID:
30129908
5.

In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment.

Rampacci E, Marenzoni ML, Chiaradia E, Passamonti F, Ricci M, Pepe M, Coletti M, Giovagnoli S.

Sci Rep. 2018 Aug 14;8(1):12149. doi: 10.1038/s41598-018-30715-z.

6.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ.

Br J Haematol. 2018 Jul;182(2):279-284. doi: 10.1111/bjh.14764. Epub 2017 May 17. No abstract available.

PMID:
29984424
7.

Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera.

Barbui T, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barosi G.

Leukemia. 2018 Sep;32(9):2077-2081. doi: 10.1038/s41375-018-0199-5. Epub 2018 Jun 28. No abstract available.

PMID:
29955128
8.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Piazza R, Magistroni V, Redaelli S, Mauri M, Massimino L, Sessa A, Peronaci M, Lalowski M, Soliymani R, Mezzatesta C, Pirola A, Banfi F, Rubio A, Rea D, Stagno F, Usala E, Martino B, Campiotti L, Merli M, Passamonti F, Onida F, Morotti A, Pavesi F, Bregni M, Broccoli V, Baumann M, Gambacorti-Passerini C.

Nat Commun. 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.

9.

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.

Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F.

Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27.

10.

Chronic myeloproliferative neoplasms in the elderly.

Maffioli M, Orlandi E, Passamonti F.

Eur J Intern Med. 2018 May 22. pii: S0953-6205(18)30182-1. doi: 10.1016/j.ejim.2018.05.005. [Epub ahead of print]

PMID:
29793825
11.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F.

Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23. No abstract available.

PMID:
29734070
12.

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.

Passamonti F, Mora B, Barraco D, Maffioli M.

Curr Hematol Malig Rep. 2018 Jun;13(3):173-182. doi: 10.1007/s11899-018-0453-y. Review.

PMID:
29713873
13.

The role of JAK2 inhibitors in MPNs 7 years after approval.

Passamonti F, Maffioli M.

Blood. 2018 May 31;131(22):2426-2435. doi: 10.1182/blood-2018-01-791491. Epub 2018 Apr 12. Review.

PMID:
29650801
14.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F.

Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5. No abstract available.

15.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G.

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Review.

PMID:
29515238
16.

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.

Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM.

Leukemia. 2018 May;32(5):1200-1210. doi: 10.1038/s41375-018-0019-y. Epub 2018 Feb 2.

17.

Antimicrobial susceptibility survey on bacterial agents of canine and feline urinary tract infections: Weight of the empirical treatment.

Rampacci E, Bottinelli M, Stefanetti V, Hyatt DR, Sgariglia E, Coletti M, Passamonti F.

J Glob Antimicrob Resist. 2018 Jun;13:192-196. doi: 10.1016/j.jgar.2018.01.011. Epub 2018 Feb 3.

PMID:
29408407
18.

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.

Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S.

Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2.

PMID:
29396713
19.

Investigation of the antibiotic resistance and biofilm formation of Staphylococcus pseudintermedius strains isolated from canine pyoderma.

Stefanetti V, Bietta A, Pascucci L, Marenzoni ML, Coletti M, Franciosini MP, Passamonti F, Casagrande Proietti P.

Vet Ital. 2017 Dec 29;53(4):289-296. doi: 10.12834/VetIt.465.2275.6.

20.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

PMID:
29275119
21.

Therapy of polycythemia vera: is it time to change?

Passamonti F, Maffioli M, Mora B.

Oncotarget. 2017 Nov 3;8(61):102759-102760. doi: 10.18632/oncotarget.22282. eCollection 2017 Nov 28. No abstract available.

22.

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A.

J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9.

PMID:
29226763
23.

Pathology in Practice.

Lepri E, Beccati F, Miglio A, Passamonti F, Veronesi F, Mandara MT.

J Am Vet Med Assoc. 2017 Nov 15;251(10):1153-1156. doi: 10.2460/javma.251.10.1153. No abstract available.

PMID:
29099246
24.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
25.

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.

Maffioli M, Mora B, Passamonti F.

Clin Adv Hematol Oncol. 2017 Sep;15(9):700-707. Review.

PMID:
28949941
26.

DNA microarray assay and real-time PCR as useful tools for studying the respiratory tract Mycoplasma populations in young dairy calves.

Bottinelli M, Passamonti F, Rampacci E, Stefanetti V, Pochiero L, Coletti M, Rueca F, Hyatt DR, Schnee C.

J Med Microbiol. 2017 Sep;66(9):1342-1349. doi: 10.1099/jmm.0.000571. Epub 2017 Sep 4.

PMID:
28868997
27.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhen H, Granier M, Assad A, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21. No abstract available.

28.

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.

Ruberti S, Bianchi E, Guglielmelli P, Rontauroli S, Barbieri G, Tavernari L, Fanelli T, Norfo R, Pennucci V, Fattori GC, Mannarelli C, Bartalucci N, Mora B, Elli L, Avanzini MA, Rossi C, Salmoiraghi S, Zini R, Salati S, Prudente Z, Rosti V, Passamonti F, Rambaldi A, Ferrari S, Tagliafico E, Vannucchi AM, Manfredini R.

Leukemia. 2018 Feb;32(2):438-449. doi: 10.1038/leu.2017.220. Epub 2017 Jul 12.

29.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

PMID:
28602585
30.

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM.

Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.

PMID:
28561069
31.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 May;31(5):1252. doi: 10.1038/leu.2017.2. No abstract available.

PMID:
28465517
32.

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas.

Merli M, Frigeni M, Gotti M, Grossi P, Bruno R, Passamonti F, Arcaini L.

Hepatology. 2017 Oct;66(4):1341-1343. doi: 10.1002/hep.29198. Epub 2017 Aug 26. No abstract available.

PMID:
28378929
33.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, Salmoiraghi S, Mannarelli C, Franci A, Paoli C, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM; AGIMM Group.

Blood. 2017 Jun 15;129(24):3227-3236. doi: 10.1182/blood-2017-01-761999. Epub 2017 Mar 28.

34.

Umbilical infections in foals: microbiological investigation and management.

Rampacci E, Passamonti F, Bottinelli M, Stefanetti V, Cercone M, Nannarone S, Gialletti R, Beccati F, Coletti M, Pepe M.

Vet Rec. 2017 Jun 3;180(22):543. doi: 10.1136/vr.103999. Epub 2017 Mar 17.

PMID:
28314783
35.

Deep sequencing and variant analysis of an Italian pathogenic field strain of equine infectious anaemia virus.

Cappelli K, Cook RF, Stefanetti V, Passamonti F, Autorino GL, Scicluna MT, Coletti M, Verini Supplizi A, Capomaccio S.

Transbound Emerg Dis. 2017 Dec;64(6):2104-2112. doi: 10.1111/tbed.12631. Epub 2017 Mar 15.

PMID:
28299895
36.

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.

Ferrario A, Merli M, Basilico C, Maffioli M, Passamonti F.

Expert Opin Investig Drugs. 2017 Mar;26(3):367-373. doi: 10.1080/13543784.2017.1288213. Epub 2017 Feb 9. Review.

PMID:
28140696
37.

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G.

Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2.

PMID:
27916398
38.

Update from the latest WHO classification of MPNs: a user's manual.

Passamonti F, Maffioli M.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):534-542. Review.

39.

A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion.

Pessina C, Basilico C, Genoni A, Meroni E, Elli L, Granata P, Righi R, Pallotti F, Mora B, Ferrario A, Passamonti F, Casalone R.

Leuk Lymphoma. 2017 Aug;58(8):1977-1980. doi: 10.1080/10428194.2016.1262952. Epub 2016 Dec 2. No abstract available.

PMID:
27911132
40.

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver R, Benevolo G, Albano F, Caramazza D, Rumi E, Merli M, Pietra D, Casalone R, Barbui T, Pieri L, Vannucchi AM.

Leukemia. 2017 Apr;31(4):970-973. doi: 10.1038/leu.2016.351. Epub 2016 Nov 25. No abstract available.

PMID:
27885272
41.

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).

Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B.

Br J Haematol. 2017 Jan;176(1):76-85. doi: 10.1111/bjh.14382. Epub 2016 Nov 8.

42.

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, McMullin MF, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP.

Leukemia. 2017 Apr;31(4):896-902. doi: 10.1038/leu.2016.300. Epub 2016 Oct 24. Erratum in: Leukemia. 2017 May;31(5):1252.

43.

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian JJ, Kröger N, McMullin MF, Passamonti F, Vannucchi A, Barbui T.

Leukemia. 2017 Apr;31(4):882-888. doi: 10.1038/leu.2016.283. Epub 2016 Oct 14.

PMID:
27740634
44.

Stored Canine Whole Blood Units: What is the Real Risk of Bacterial Contamination?

Miglio A, Stefanetti V, Antognoni MT, Cappelli K, Capomaccio S, Coletti M, Passamonti F.

J Vet Intern Med. 2016 Nov;30(6):1830-1837. doi: 10.1111/jvim.14593. Epub 2016 Oct 13.

45.

Detection of bacterial contamination and DNA quantification in stored blood units in 2 veterinary hospital blood banks.

Stefanetti V, Miglio A, Cappelli K, Capomaccio S, Sgariglia E, Marenzoni ML, Antognoni MT, Coletti M, Mangili V, Passamonti F.

Vet Clin Pathol. 2016 Sep;45(3):406-10. doi: 10.1111/vcp.12372. Epub 2016 Jul 11.

PMID:
27642138
46.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

47.

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.

Merli M, Ferrario A, Maffioli M, Olivares C, Stasia A, Arcaini L, Passamonti F.

Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14. Review.

PMID:
27416486
48.

Management of Candida guilliermondii joint infection in a dog.

Bufalari A, Maggio C, Moretti G, Crovace A, Stefanetti V, Straubinger RK, Passamonti F.

Acta Vet Scand. 2016 Jul 8;58(1):47. doi: 10.1186/s13028-016-0227-2.

49.

Detection and DNA quantification of Enterococcus casseliflavus in a foal with septic meningitis.

Stefanetti V, Beccati F, Passamonti F, Sgariglia E, Coletti M, Vuerich M, Marenzoni ML.

J Am Vet Med Assoc. 2016 Jul 1;249(1):96-100. doi: 10.2460/javma.249.1.96.

PMID:
27308888
50.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pieri L, Fjerza R, Pietra D, Cilloni D, Sant'Antonio E, Salmoiraghi S, Passamonti F, Rambaldi A, Barosi G, Barbui T, Cazzola M, Vannucchi AM.

Am J Hematol. 2016 Sep;91(9):918-22. doi: 10.1002/ajh.24442. Epub 2016 Jul 4.

Supplemental Content

Loading ...
Support Center